Literature DB >> 26505824

Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study.

Cathrine Laustrup Møller1, Dorte Vistisen1, Kristine Færch1, Nanna Borup Johansen1, Daniel R Witte1, Anna Jonsson1, Oluf Pedersen1, Torben Hansen1, Torsten Lauritzen1, Marit E Jørgensen1, Signe S Torekov1, Jens Juul Holst1.   

Abstract

CONTEXT: Glucose-dependent insulinotropic polypeptide (GIP) may increase lipid clearance by stimulating lipid uptake. However, given that GIP promotes release of insulin by the pancreas and insulin is anti-lipolytic, the effect may be indirect.
OBJECTIVE: In this study we examined the association between GIP and lipid metabolism in individuals with low to high risk of type 2 diabetes and assessed whether the associations were modified by or mediated through insulin. DESIGN, SETTING, AND PARTICIPANTS: Analyses were based on the Danish cross-sectional ADDITION-PRO study (n = 1405). Lipid metabolism was measured by fasting plasma lipids and obesity including abdominal fat distribution assessed by ultrasonography. GIP and insulin were measured during an oral glucose tolerance test (0, 30 and 120 min). Linear regression analysis was used to study the associations between GIP, plasma lipids, and obesity measures.
RESULTS: A doubling in fasting GIP levels was associated with lower low-density lipoprotein in both men (mean [95% CI] -0.10 mmol/l [-0.18--0.03]) and women (-0.14 mmol/l [-0.23--0.04]) and with higher high-density lipoprotein in women (0.06 mmol/l [-0.02-0.10]). In men, a doubling in stimulated GIP was associated with 0.13 cm less 0.01-0.25 sc fat but with more visceral abdominal fat (0.45 cm [0.12-0.78]) and higher waist-hip ratio (0.011 [0.004-0.019]).
CONCLUSIONS: Contrary to what was previously thought, GIP may be associated with improved low-density lipoprotein clearance but with an unhealthy fat distribution independent of insulin. The effect of GIP on obesity measures was substantially different between men and women. The potential effect of GIP on visceral and sc adipose tissue physiology warrants further examination.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26505824     DOI: 10.1210/jc.2015-3133

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels.

Authors:  J Góralska; U Raźny; A Polus; J Stancel-Możwiłło; M Chojnacka; A Gruca; A Zdzienicka; A Dembińska-Kieć; B Kieć-Wilk; B Solnica; M Malczewska-Malec
Journal:  Int J Obes (Lond)       Date:  2017-12-13       Impact factor: 5.095

2.  The Enteroendocrine System in Obesity.

Authors:  Emily L Miedzybrodzka; Frank Reimann; Fiona M Gribble
Journal:  Handb Exp Pharmacol       Date:  2022

3.  The effect of glucose-dependent insulinotropic polypeptide (GIP) variants on visceral fat accumulation in Han Chinese populations.

Authors:  T Wang; X Ma; T Tang; K Higuchi; D Peng; R Zhang; M Chen; J Yan; S Wang; D Yan; Z He; F Jiang; Y Bao; W Jia; K Ishida; C Hu
Journal:  Nutr Diabetes       Date:  2017-05-22       Impact factor: 5.097

4.  Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.

Authors:  Piotr A Mroz; Brian Finan; Vasily Gelfanov; Bin Yang; Matthias H Tschöp; Richard D DiMarchi; Diego Perez-Tilve
Journal:  Mol Metab       Date:  2018-12-05       Impact factor: 7.422

Review 5.  Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH.

Authors:  Brian Finan; Sebastian D Parlee; Bin Yang
Journal:  Mol Metab       Date:  2020-12-23       Impact factor: 7.422

Review 6.  Metformin: Expanding the Scope of Application-Starting Earlier than Yesterday, Canceling Later.

Authors:  Yulia A Kononova; Nikolai P Likhonosov; Alina Yu Babenko
Journal:  Int J Mol Sci       Date:  2022-02-21       Impact factor: 5.923

Review 7.  Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.

Authors:  Christoffer Clemmensen; Brian Finan; Timo D Müller; Richard D DiMarchi; Matthias H Tschöp; Susanna M Hofmann
Journal:  Nat Rev Endocrinol       Date:  2019-02       Impact factor: 43.330

Review 8.  Searching for the physiological role of glucose-dependent insulinotropic polypeptide.

Authors:  Jens Juul Holst; Johanne Agerlin Windeløv; Geke Aline Boer; Jens Pedersen; Berit Svendsen; Mikkel Christensen; Signe Torekov; Meena Asmar; Bolette Hartmann; Anne Nissen
Journal:  J Diabetes Investig       Date:  2016-04-18       Impact factor: 4.232

9.  Wheat-derived arabinoxylan oligosaccharides with bifidogenic properties abolishes metabolic disorders induced by western diet in mice.

Authors:  Audrey M Neyrinck; Sophie Hiel; Caroline Bouzin; Vicenta Garcia Campayo; Patrice D Cani; Laure B Bindels; Nathalie M Delzenne
Journal:  Nutr Diabetes       Date:  2018-03-07       Impact factor: 5.097

10.  Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study.

Authors:  Amra Jujić; Naeimeh Atabaki-Pasdar; Peter M Nilsson; Peter Almgren; Liisa Hakaste; Tiinamaija Tuomi; Lisa M Berglund; Paul W Franks; Jens J Holst; Rashmi B Prasad; Signe S Torekov; Susana Ravassa; Javier Díez; Margaretha Persson; Olle Melander; Maria F Gomez; Leif Groop; Emma Ahlqvist; Martin Magnusson
Journal:  Diabetologia       Date:  2020-01-23       Impact factor: 10.122

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.